

Table 1.1.E.1-9: Key Safety and Efficacy Variables for Eyes Treated for Low Myopia

N	1 Month		3 Months		6 Months		12 Months		18 Months		24 Months	
	n/N	%	n/N	%	n/N	%	n/N	%	n/N	%	n/N	%
<b>EFFICACY VARIABLES</b>												
MRSE $\pm$ 0.50 D	408	59.5	359	62.8	278	61.6	144	67.0	39	66.1	28	71.8
MRSE $\pm$ 1.00 D	160	23.3	122	21.3	93	20.6	37	17.2	10	16.9	5	12.8
MRSE $\pm$ 2.00 D	63	9.2	51	8.9	34	7.5	14	6.5	4	6.8	2	5.1
MRSE $\pm$ 1.00 D (cumulative)	568	82.8	481	84.1	371	82.3	181	84.2	49	83.1	33	84.6
MRSE $\pm$ 2.00 D (cumulative)	631	92.0	532	93.0	405	89.8	195	90.7	53	89.8	35	89.7
Eyes Without Monovision												
# Non-Monovision (N)	314		260		202		99		23		13	
UCVA 20/20 or better	142	45.2	150	57.7	123	60.9	64	64.6	11	47.8	9	69.2
UCVA 20/25 to 20/40	153	48.7	99	38.1	74	36.6	33	33.3	13	52.2	3	23.1
(cumulative)	295	93.9	249	95.8	197	97.5	97	98.0	23	100.0	12	92.3
<b>SAFETY VARIABLES</b>												
Loss of > 2 lines BSCVA	6	0.9	1	0.2	0	0.0	0	0.0	0	0.0	0	0.0
BSCVA worse than 20/40	3	0.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Increase > 2 D cylinder	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
BSCVA worse than 20/25 if 20/20 or better preop	21	3.1	3	0.5	3	0.7	4	1.9	0	0.0	0	0.0